153 related articles for article (PubMed ID: 17768830)
21. Utilisation of intravenous immunoglobulin in New Zealand: a clinical audit.
Hutchinson D; Flanagan P; Charlewood R; Mitchell T
N Z Med J; 2006 Dec; 119(1246):U2340. PubMed ID: 17151714
[TBL] [Abstract][Full Text] [Related]
22. Intravenous immunoglobulin in autoimmune and inflammatory diseases: more than mere transfer of antibodies.
Sibéril S; Elluru S; Negi VS; Ephrem A; Misra N; Delignat S; Bayary J; Lacroix-Desmazes S; Kazatchkine MD; Kaveri SV
Transfus Apher Sci; 2007 Aug; 37(1):103-7. PubMed ID: 17765663
[TBL] [Abstract][Full Text] [Related]
23. A multicenter drug use surveillance of intravenous immunoglobulin utilization in US academic health centers.
Chen C; Danekas LH; Ratko TA; Vlasses PH; Matuszewski KA
Ann Pharmacother; 2000 Mar; 34(3):295-9. PubMed ID: 10917372
[TBL] [Abstract][Full Text] [Related]
24. Immunomodulatory effects of intravenous immunoglobulins as a treatment for autoimmune diseases, cancer, and recurrent pregnancy loss.
Sapir T; Blank M; Shoenfeld Y
Ann N Y Acad Sci; 2005 Jun; 1051():743-78. PubMed ID: 16127014
[TBL] [Abstract][Full Text] [Related]
25. European Guidelines (S1) on the use of high-dose intravenous immunoglobulin in dermatology.
Enk A; Hadaschik E; Eming R; Fierlbeck G; French L; Girolomoni G; Hertl M; Jolles S; Karpati S; Steinbrink K; Stingl G; Volc-Platzer B; Zillikens D
J Dtsch Dermatol Ges; 2017 Feb; 15(2):228-241. PubMed ID: 28036140
[TBL] [Abstract][Full Text] [Related]
26. Should therapeutic immunoglobulin be considered a generic product? An evidence-based approach.
Misbah SA
J Allergy Clin Immunol Pract; 2013; 1(6):567-72. PubMed ID: 24565702
[TBL] [Abstract][Full Text] [Related]
27. [IgIV at home:experience of a center--economic aspects].
Hachulla E
Rev Med Interne; 2007 May; 28 Spec No. 1():7-10. PubMed ID: 17768832
[TBL] [Abstract][Full Text] [Related]
28. [The use of intravenous immunoglobulins in the treatment of primary immunodeficiencies].
Lewandowicz-Uszyńska A; Jankowski A
Pol Merkur Lekarski; 2011 Jun; 30(180):409-12. PubMed ID: 21751549
[TBL] [Abstract][Full Text] [Related]
29. Intravenous immunoglobulin utilization in the Canadian Atlantic provinces: a report of the Atlantic Collaborative Intravenous Immune Globulin Utilization Working Group.
Constantine MM; Thomas W; Whitman L; Kahwash E; Dolan S; Smith S; Caudle CJ; Burton E; Anderson DR;
Transfusion; 2007 Nov; 47(11):2072-80. PubMed ID: 17958537
[TBL] [Abstract][Full Text] [Related]
30. Use of Polyclonal Intravenous Immunoglobulin at a Paediatric Referral Hospital in South Africa Between 2009 and 2012.
Raiman S; Knight SE; Eley B; Welzel TB
J Clin Immunol; 2015 Oct; 35(7):668-74. PubMed ID: 26369911
[TBL] [Abstract][Full Text] [Related]
31. High-resolution physicochemical characterization of different intravenous immunoglobulin products.
Washburn N; Meccariello R; Hu S; Hains M; Bhatnagar N; Sarvaiya H; Kapoor B; Schaeck J; Pino I; Manning A; Lansing JC; Bosques CJ
PLoS One; 2017; 12(7):e0181251. PubMed ID: 28759653
[TBL] [Abstract][Full Text] [Related]
32. [Use of intravenous polyclonal immunoglobulins in autoimmune and inflammatory disorders].
Graff-Dubois S; Sibéril S; Elluru S; Negi VS; Delignat S; Mouthon L; Lacroix-Desmazes S; Kazatchkine MD; Bayary J; Kaveri SV
Transfus Clin Biol; 2007 May; 14(1):63-8. PubMed ID: 17498995
[TBL] [Abstract][Full Text] [Related]
33. How intravenous immunoglobulin is used in clinical practice: audits of two Sydney teaching hospitals.
Lin MW; Kirkpatrick PE; Riminton DS
Intern Med J; 2007 May; 37(5):308-14. PubMed ID: 17504278
[TBL] [Abstract][Full Text] [Related]
34. Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systematic review and meta-analysis.
Laupland KB; Kirkpatrick AW; Delaney A
Crit Care Med; 2007 Dec; 35(12):2686-92. PubMed ID: 18074465
[TBL] [Abstract][Full Text] [Related]
35. Intravenous immunoglobulin therapy: the process, the product, the patient, and the pocketbook. Introduction.
Harvey RD
Pharmacotherapy; 2005 Nov; 25(11 Pt 2):71S-72S. PubMed ID: 16229676
[No Abstract] [Full Text] [Related]
36. Intravenous immunoglobulin therapy for autoimmune diseases.
Arnson Y; Shoenfeld Y; Amital H
Autoimmunity; 2009 Sep; 42(6):553-60. PubMed ID: 19657774
[TBL] [Abstract][Full Text] [Related]
37. Pneumococcal antibody levels in children with PID receiving immunoglobulin.
Tuerlinckx D; Florkin B; Ferster A; De Schutter I; Chantrain C; Haerynck F; Philippet P; Strengers P; Laub R
Pediatrics; 2014 Jan; 133(1):e154-62. PubMed ID: 24366995
[TBL] [Abstract][Full Text] [Related]
38. [IgM enriched immunoglobulins as a therapy for sepsis and autoimmune diseases].
Yehudai D; Vadasz Z
Harefuah; 2012 Mar; 151(3):171-4, 188. PubMed ID: 22519268
[TBL] [Abstract][Full Text] [Related]
39. Regulatory and reimbursement issues in treating patients with immune-mediated neuropathies.
Donofrio PD; Busis NA
Neurology; 2002 Dec; 59(12 Suppl 6):S41-5. PubMed ID: 12499470
[TBL] [Abstract][Full Text] [Related]
40. IVIg therapy in autoimmunity and related disorders: our experience with a large cohort of patients.
Shoenfeld Y; Katz U
Autoimmunity; 2005 Mar; 38(2):123-37. PubMed ID: 16040333
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
